For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 5,593,078 | |||
| Research and development | 265,570 | |||
| Total operating expenses | 5,858,648 | |||
| Loss from operations | -5,858,648 | |||
| Net gain from change in fair value of derivative liability instrument | 2,574,971 | |||
| Gain from change in fair value of forward contract liability | -380,442 | |||
| Amortization of deferred offering cost | 496,948 | |||
| Interest income | 29,583 | |||
| Other income | 176,520 | |||
| Total other income | 2,664,568 | |||
| Net loss | -3,194,080 | |||
| Basic EPS | -0.12 | |||
| Diluted EPS | -0.12 | |||
| Basic Average Shares | 27,716,045 | |||
| Diluted Average Shares | 27,716,045 | |||
Turn Therapeutics Inc. (TTRX)
Turn Therapeutics Inc. (TTRX)